Clinical trials: Injection Drug Use
Substance Abuse, Intravenous, HIV
Change the Cycle: An RCT to Prevent Injection Initiation
The study will test the efficacy of a hour long, one-on-one, active listening counseling session (called Change the Cycle or CTC) aimed at reducing behaviors among active people who inject drugs (PWID) that research has found to…
- Conditions
- Substance Abuse, Intravenous, HIV, Heroin Dependence, Opioid Dependence
- Trial name
- CTC (NCT02774954)
- Testing
- Change the Cycle
- Where
- 2 sites in United States
- Volunteers
- 979 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Neovascular Age-related Macular Degeneration (nAMD)
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe
This was an open-label, single arm, multicenter, Phase IIIb study in subjects with (wet) nAMD, eligible for IVT aflibercept treatment.
- Trial name
- NCT05161806
- Testing
- SOK583A1 (40 mg/mL), Prefilled Syringe (PFS)
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Sandoz
Hepatitis C, Chronic
A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3
This sudy will determine whether shortening treatment for hepatitis C is feasible, safe and effective for patients who are current injection drug users or receiving opiate substitution therapy and who are responding well to…
- Trial name
- ACTIVATE (NCT01364090)
- Testing
- Pegylated interferon alfa 2b, Ribavirin
- Where
- 17 sites in Australia, Belgium and 5 more
- Volunteers
- 93 people
- Sponsor
- Kirby Institute
Asthma
Long Term Special Drug Use Investigation of Mepolizumab
This study is a special drug use investigation program of NUCALA (a brand name for Mepolizumab) administered subcutaneously (SC).
- Trial name
- NCT03028480
- Testing
- NUCALA Injection
- Volunteers
- 1,061 people
- Sponsor
- GlaxoSmithKline
HIV/AIDS
Packaging PrEP to Prevent HIV Among WWID
Evidence suggests women who inject drugs (WWID) are disproportionately vulnerable to HIV. If HIV incidence continues unchecked, 1 in 23 WWID in the United States will acquire HIV.
- Trial name
- NCT03304912
- Testing
- PrEP Education and option to accept a PrEP prescription
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Drexel University
Hepatitis C, Opioid-Related Disorders
The Kentucky Viral Hepatitis Treatment Study
The overarching goal of the Kentucky Viral Hepatitis Treatment Project (KeY Treat) is to increase hepatitis C virus (HCV) treatment access and delivery in a rural Appalachian community, which is in the midst of the…
- Conditions
- Hepatitis C, Opioid-Related Disorders, Injection Drug Use
- Trial name
- KeY Treat (NCT03949764)
- Testing
- Sofosbuvir/velpatasvir (Epclusa®)
- Where
- United States
- Volunteers
- 380 people
- Sponsor
- Jennifer Havens
Labor Pain
Programmed Intermittent Epidural Bolus Time Interval and Injection Volume
Studies suggest that administration of maintenance epidural solutions as programmed or automated intermittent boluses, rather than continuous infusions, result in lower bupivacaine consumption, decreased need for manual boluses…
- Trial name
- NCT00417027
- Testing
- Programmed Intermittent Epidural Bolus (PIEB)
- Where
- United States
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Hepatitis C
Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs
The investigator's hypothesis is that active injectors will show a partial reduction in markers of immune activation with HCV therapy whereas non-injectors will show a more significant reduction in these markers, and will exhibit…
- Trial name
- NCT02347345
- Testing
- Harvoni (Fixed dose combination ledipasvir/sofosbuvir)
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
Prostate Cancer
Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for "Prostate Cancer"
The purpose of this study is to evaluate the safety in patients with prostate cancer receiving the drug in the routine clinical setting.
- Trial name
- NCT03209492
- Testing
- Leuprorelin acetate
- Where
- Japan
- Volunteers
- 333 people
- Sponsor
- Takeda
Opioid Use Disorder
Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations
Extended-release buprenorphine (SUBLOCADE®) injection is currently approved for subcutaneous administration in the abdomen for treatment of opioid use disorder (OUD).
- Trial name
- NCT05704543
- Testing
- Buprenorphine Extended-Release Injection
- Where
- 6 sites in United States
- Volunteers
- 132 people
- Sponsor
- Indivior Inc.
Drug Use, Opioid-use Disorder
Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections
This study will assess the efficacy of an integrated outpatient treatment model for persons with opioid use disorder and injection related infections.
- Trial name
- BOPAT (NCT04677114)
- Testing
- Buprenorphine and Outpatient Parenteral Antibiotic Therapy, Buprenorphine and standard of care antibiotic treatment
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Laura Fanucchi
HIV Infections, Stigmatization
Stigma, Risk Behaviors and Health Care Among HIV-infected Russian People Who Inject Drugs
This study is a randomized controlled trial (RCT) among 100 HIV-positive people with injection drug use, which aims to test the feasibility of the SCRIPT intervention and evaluate its effectiveness on the reduction of…
- Conditions
- HIV Infections, Stigmatization, Substance Use
- Trial name
- SCRIPT (NCT03695393)
- Testing
- ACT Therapy
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Boston Medical Center
Prostate Cancer
Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey "Long-term Use Survey in Prostate Cancer Patients (96 Weeks)"
The purpose of this survey is designed to evaluate the efficacy and safety of long-term use (96 weeks) of leuprorelin acetate SR 11.25 milligram (mg) injection kit (Leuplin SR 11.25 mg injection kit) in prostate cancer…
- Trial name
- NCT02167893
- Testing
- Leuprorelin acetate
- Volunteers
- 11,288 people
- Sponsor
- Takeda